| Bioactivity | 3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study[1]. | ||||||||||||
| In Vivo | 3,4-Dehydro Cilostazol (OPC-13015; Oral; 1 mg/kg GLZ and 10 mg/kg CLZ) has a T1/2 of 3.94 hours, a Cmax of 1.39 μM and an AUC0-24 of 4.69 μg•h/ml. The plasma concentration time profiles of GLZ, CLZ & its active metabolite DCLZ are traceable up to 24 h, 12 h and 12 h respectively by oral administration at 1 mg/kg dose of GLZ and 10 mg/kg CLZ[1]. Animal Model: | ||||||||||||
| Name | 3,4-Dehydro Cilostazol | ||||||||||||
| CAS | 73963-62-9 | ||||||||||||
| Formula | C20H25N5O2 | ||||||||||||
| Molar Mass | 367.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. T R S Satheeshmanikandan, et al. Liquid Chromatography - Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and Its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study. Arzneimi |